NASDAQ · Biotechnology

Monopar Therapeutics Inc. (MNPR) Stock

$78.96 -5.98% NASDAQ: MNPR Healthcare

Valuation

MetricValue
Price$78.96
Market Cap$528.96M
P/E Ratio-33.46
P/B Ratio5.11
P/S Ratio0.00
EPS (TTM)$-1.85
52-Week High$124.82
52-Week Low$50.07
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-13.08%
ROA-13.22%
ROCE-16.89%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio51.36

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-9.0M$-11.0M$-9.0M$-16.0M$-17.0M
Net Profit$-9.0M$-11.0M$-8.0M$-16.0M$-14.0M
EPS$-0.73$-0.83$-0.58$-1.36$-1.85
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$21.0M$13.0M$7.0M$60.0M$141.0M
Total Liabilities$2.0M$3.0M$2.0M$5.0M$3.0M
Cash$20.0M$8.0M$7.0M$46.0M$62.0M
Borrowings$0$0$0$0$0

Latest News

Monopar Therapeutics Begins Rolling Application for ALXN1840 in Wilson Disease MT Newswires · Jul 22, 2026 Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease GlobeNewswire · Jul 22, 2026 Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team GlobeNewswire · Jul 20, 2026 Monopar Therapeutics Says ALXN1840 Receives FDA Rare Pediatric Disease Designation in Wilson Disease MT Newswires · Jun 30, 2026 Monopar Therapeutics Receives FDA Rare Pediatric Disease Designation for ALXN1840 for the Treatment of Wilson Disease GlobeNewswire · Jun 30, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-7.0M$-7.0M$-8.0M$-6.0M$-12.0M
Investing Cash Flow$0$-5.0M$5.0M$-14.0M$-63.0M
Financing Cash Flow$0$0$0$0$-36.0M
Net Cash Flow$4.0M$-12.0M$-1.0M$39.0M$16.0M
Free Cash Flow$-7.0M$-7.0M$-8.0M$-6.0M$-12.0M

Valuation & Return Ratios

MetricValue
PEG Ratio1.17
EV / EBITDA-25.50
FCF Yield-620.89%
Quick Ratio33.56
Interest Coverage0.00
Return 1Y125.52%
Return 3Y2685.24%
Return 5Y299.16%

Ownership

Insiders Held23.42%
Institutions Held95.19%
Institutions Float Held124.30%
Institutional HolderSharesReport Date
Janus Henderson Group PLC1,317,4102026-03-31
RA Capital Management, L.P.667,2072026-03-31
Saturn V Capital Management LP345,6262026-03-31
Deerfield Management Company, L.P323,7452026-03-31
Blackrock Inc.316,5672026-03-31

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADCTADC Therapeutics SA $1.73 +8.81% -2.14 $220.04M 0.00%
ALXOALX Oncology Holdings Inc. $1.25 +5.93% -1.08 $168.20M 0.00%
ATNMActinium Pharmaceuticals, Inc. (Delaware) $1.10 +1.85% 3.25 $34.51M 0.00%
BCYCBicycle Therapeutics plc $4.22 +0.24% -1.34 $292.84M 0.00%
CMPXCompass Therapeutics, Inc. $0.99 +0.98% -2.06 $178.83M 0.00%

About Monopar Therapeutics Inc.

Monopar Therapeutics Inc. is led by CEO Chandler D. Robinson, employs 14 people, headquartered in US, publicly traded since 2019.

Monopar Therapeutics Inc. (MNPR) stock trades at $78.96 with a market capitalization of $528.96M. The stock is valued at a price-to-earnings (P/E) ratio of -33.46, price-to-book of 5.11, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $50.07 and $124.82, and currently trades 36.7% below its 52-week high.

On profitability, Monopar Therapeutics Inc. generates a return on equity (ROE) of -13.08%, return on capital employed of -16.89%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides